The safety and efficacy of AFLURIA QUADRIVALENT in persons less than 6 months of age have not been established.1 The PharmaJet® Stratis® Needle-Free Injection System is not approved as a method of administering AFLURIA to persons less than 18 and greater than 64 years of age due to lack...
Administered by needle and syringe (AFLURIA QUADRIVALENT data): In children 6 months through 35 months of age, the most commonly reported injection-site reactions were pain and redness (≥ 20%). The most common systemic adverse reactions were irritability (≥ 30%), diarrhea and loss of appetite...
Administered by needle and syringe (AFLURIA QUADRIVALENT data): In children 6 months through 35 months of age, the most commonly reported injection-site reactions were pain and redness (≥ 20%). The most common systemic adverse reactions were irritability (≥ 30%), diarrhea and loss of appetite...
Administered by needle and syringe (AFLURIA QUADRIVALENT data): In children 6 months through 35 months of age, the most commonly reported injection-site reactions were pain and redness (≥ 20%). The most common systemic adverse reactions were irritability (≥ 30%), diarrhea and loss of appetite...